Skip to main content
SpringerLink
Log in

Mise au point sur le traitement médical du cancer du rein métastatique

Medical management of metastatic kidney cancer, a literature review

  • Article de Synthèse / Review Article
  • Published:
Journal africain du cancer / African Journal of Cancer

Résumé

Le cancer du rein représente 2 à 3 % des tumeurs malignes de l’adulte. En situation métastatique, le traitement standard était les cytokines, puisque le cancer du rein est chimiorésistant, et la survie à cinq ans était inférieure à 10 %. La tumeur du rein est hypervascularisée. La bonne connaissance des mécanismes de biologie moléculaires a permis de mieux comprendre les phénomènes d’angiogenèse, élément clé de la prolifération tumorale, et donc d’identifier de nouvelles cibles thérapeutiques, ce qui a donné naissance aux thérapeutiques ciblées, transformant les stratégies thérapeutiques.

Abstract

Kidney cancer accounts for 2 to 3% of malignant tumors in adults. For metastatic forms, the standard treatment has been cytokines because kidney cancer is resistant to chemotherapy, and survival at five years was less than 10%. Kidney tumors are highly vascularised. Angiogenesis, the key element of tumor proliferation, is now better understood with a good knowledge of the mechanisms of molecular biology. Now we can identify new therapeutic targets, giving rise to targeted therapies, transforming therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal-cell carcinoma. J Clin Oncol 23(4):832–841

    Article  PubMed  Google Scholar 

  2. Medical Research Council Renal Cancer Collaborators (1999) Interferon alfa and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353(9146):14–17

    Article  Google Scholar 

  3. Pyrhönen S, Salminen E, Ruutu M, et al (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine vs vinblastine alone in patients with advanced renal-cell cancer. J Clin Oncol 17(9):2859–2867

    PubMed  Google Scholar 

  4. Negrier S, Perol D, Ravaud A, et al (2005) Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY QUATTRO trial. J Clin Oncol ASCO Annual Meeting Proceedings 23: no 16S, part I of II

  5. Bernards R (2003) Cancer: cues for migration. Nature 425:247–248

    Article  PubMed  CAS  Google Scholar 

  6. Kaelin WG (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673–682

    Article  PubMed  CAS  Google Scholar 

  7. Yang J, Haworth L, Richard M, et al (2003) A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. New Engl J Med 349:427–434

    Article  PubMed  CAS  Google Scholar 

  8. Escudier B, Pluzanska A, Koralewski P, et al (2007) AVOREN trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal-cell carcinoma: a randomised, double blind phase III trial. Lancet 370:2103–2111

    Article  PubMed  Google Scholar 

  9. Rini BI, Halabi S, Rosenberg JE, et al (2008) Phase III trial of bevacizumab plus interferon-alfa vs interferon-alfa monotherapy. CALGB 90206 study. ASCO GU J Clin Oncol 26(33): 5422–5428 (Epub 2008 Oct 20 abstract 350: 267)

    Article  CAS  Google Scholar 

  10. Motzer RJ, Bander NH, Nanus DM, et al (2007) Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): updated results of two-phase II trials and prognostic factor analysis for survival. Proc Am Soc Clin Oncol (abstract # 5095)

  11. Motzer RJ, Hutsson TE, Tomczak P, et al (2007) Sunitinib vs interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

    Article  PubMed  CAS  Google Scholar 

  12. Ratain MJ, Eisen T, Stadler WM, et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal-cell carcinoma. J Clin Oncol 24(16):2505–2512 (Epub 2006 Apr 24)

    Article  PubMed  CAS  Google Scholar 

  13. Escudier B, Eisen T, Walter M, et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134

    Article  PubMed  CAS  Google Scholar 

  14. Hudes G, Carducci M, Tomczak P, et al (2007) Temsirolimus, interferon alfa or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281

    Article  PubMed  CAS  Google Scholar 

  15. Motzer RJ, Escudier B, Oudard S, et al (2008) Efficacy of everolimus in advanced renal-cell carcinoma: a double blind, randomised, placebo-controlled phase III trial. Lancet 9: 372(9637):449–456

    Article  CAS  Google Scholar 

  16. Mickisch GH, Garin A, van Poppel H, et al (2001) European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286):966–970

    Article  PubMed  CAS  Google Scholar 

  17. Flanigan RC, Salmon SE, Blumenstein BA, et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345(23):1655–1659

    Article  PubMed  CAS  Google Scholar 

  18. Mottet N (2006) Role of nephrectomy in metastatic renal-cell carcinoma. Ann Urol 40(5):273–279

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie médicale, institut national d’oncologie, BP 6213, Rabat, Maroc

    N. Mellas & H. Errihani

  2. Service d’urologie, CHU Hassan-II, BP 7206, Fès Zouhour, 30014, Fès, Maroc

    S. Mellas

  3. Service de radiothérapie-oncologie, institut national d’oncologie, BP 6213, Rabat, Maroc

    O. Masbah

Authors
  1. N. Mellas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Mellas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. Masbah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Errihani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Mellas.

About this article

Cite this article

Mellas, N., Mellas, S., Masbah, O. et al. Mise au point sur le traitement médical du cancer du rein métastatique. J Afr Cancer 1, 154–158 (2009). https://doi.org/10.1007/s12558-009-0029-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12558-009-0029-9

Mots clés

Keywords

Search

Navigation